Volume 15, Issue 8, Pages (July 2014)

Slides:

Advertisements

Similar presentations

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac)

Advertisements

Volume 14, Issue 12, Pages (November 2013)

Volume 14, Issue 4, Pages (April 2013)

Volume 12, Issue 9, Pages (September 2011)

Volume 16, Issue 2, Pages (February 2015)

Volume 18, Issue 10, Pages (October 2017)

Volume 18, Issue 6, Pages (June 2017)

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

Volume 18, Issue 7, Pages (July 2017)

Volume 16, Issue 9, Pages (September 2015)

Volume 15, Issue 6, Pages (May 2014)

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9779, Pages (May 2011)

Volume 377, Issue 9783, Pages (June 2011)

Volume 371, Issue 9611, Pages (February 2008)

Volume 9, Issue 5, Pages (May 2008)

Volume 15, Issue 8, Pages (July 2014)

Volume 15, Issue 2, Pages (February 2014)

Volume 15, Issue 4, Pages (April 2014)

Volume 374, Issue 9707, Pages (December 2009)

Volume 15, Issue 4, Pages (April 2014)

Volume 373, Issue 9663, Pages (February 2009)

Volume 2, Issue 6, Pages (June 2015)

Volume 14, Issue 8, Pages (July 2013)

Volume 18, Issue 7, Pages (July 2017)

Volume 14, Issue 8, Pages (July 2013)

Volume 12, Issue 7, Pages (July 2011)

Volume 15, Issue 6, Pages (May 2014)

Volume 16, Issue 6, Pages (June 2015)

Volume 18, Issue 3, Pages (March 2017)

Volume 379, Issue 9812, Pages (January 2012)

Volume 15, Issue 1, Pages (January 2014)

Volume 387, Issue 10023, Pages (March 2016)

Volume 6, Issue 6, Pages (June 2005)

Volume 389, Issue 10073, Pages (March 2017)

Volume 14, Issue 6, Pages (May 2013)

Volume 11, Issue 4, Pages (April 2010)

Volume 20, Issue 1, Pages (January 2019)

Volume 14, Issue 11, Pages (October 2013)

Volume 381, Issue 9868, Pages (March 2013)

Volume 18, Issue 3, Pages (March 2017)

Volume 385, Issue 9962, Pages (January 2015)

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Volume 19, Issue 4, Pages (April 2018)

Volume 15, Issue 8, Pages (July 2014)

Volume 16, Issue 15, Pages (November 2015)

Volume 9, Issue 4, Pages (April 2008)

Volume 15, Issue 6, Pages (May 2014)

Volume 14, Issue 6, Pages (May 2013)

Volume 13, Issue 11, Pages (November 2012)

Volume 16, Issue 15, Pages (November 2015)

Volume 5, Issue 4, Pages (April 2018)

Volume 16, Issue 8, Pages (August 2015)

Volume 14, Issue 8, Pages (July 2013)

Volume 15, Issue 6, Pages (May 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 11, Issue 3, Pages (March 2010)

Volume 11, Issue 1, Pages (January 2010)

Volume 18, Issue 10, Pages (October 2017)

Volume 375, Issue 9715, Pages (February 2010)

Volume 376, Issue 9747, Pages (October 2010)

Volume 14, Issue 9, Pages (August 2013)

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Volume 13, Issue 5, Pages (May 2012)

Volume 5, Issue 1, Pages (January 2018)

Recurrence after low-dose radioiodine ablation and recombinant human thyroid- stimulating hormone for differentiated thyroid cancer (HiLo): long-term results.

Volume 14, Issue 7, Pages (June 2013)

Volume 371, Issue 9611, Pages (February 2008)

Volume 20, Issue 7, Pages (July 2019)

Presentation transcript:

Volume 15, Issue 8, Pages 829-840 (July 2014) Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial Prof Gary Middleton, MD, Paul Silcocks, BMBCh, Trevor Cox, PhD, Prof Juan Valle, MD, Jonathan Wadsley, MA, David Propper, MD, Fareeda Coxon, MBBS, Paul Ross, PhD, Srinivasan Madhusudan, PhD, Tom Roques, BMBCh, Prof David Cunningham, MD, Stephen Falk, MD, Nick Wadd, FRCP, Mark Harrison, PhD, Pippa Corrie, FRCP, Tim Iveson, MD, Angus Robinson, FRCR, Karen McAdam, FRCP, Martin Eatock, FRCP, Prof Jeff Evans, MD, Caroline Archer, MBBS, Tamas Hickish, FRCP, Angel Garcia-Alonso, MD, Marianne Nicolson, FRCP, Prof William Steward, PhD, Alan Anthoney, PhD, William Greenhalf, PhD, Victoria Shaw, PhD, Eithne Costello, PhD, Dean Naisbitt, PhD, Charlotte Rawcliffe, MSc, Gemma Nanson, BSc, Prof John Neoptolemos, MD The Lancet Oncology Volume 15, Issue 8, Pages 829-840 (July 2014) DOI: 10.1016/S1470-2045(14)70236-0 Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet Oncology 2014 15, 829-840DOI: (10.1016/S1470-2045(14)70236-0) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier curves of overall survival (A) and forest plot by key subgroups (B, C) The Lancet Oncology 2014 15, 829-840DOI: (10.1016/S1470-2045(14)70236-0) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 3 Time to progression by treatment group Time to progression was defined as time to progression or progression-related death with censoring of deaths from other causes. The Lancet Oncology 2014 15, 829-840DOI: (10.1016/S1470-2045(14)70236-0) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 4 Overall survival according to a positive or negative delayed-type hypersensitivity response in patients assigned to chemoimmunotherapy (A) Patients randomly assigned to sequential chemoimmunotherapy, conditional on reaching week 18. (B) Patients randomly assigned to concurrent chemoimmunotherapy, conditional on reaching week 10. The Lancet Oncology 2014 15, 829-840DOI: (10.1016/S1470-2045(14)70236-0) Copyright © 2014 Elsevier Ltd Terms and Conditions